UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review

ClinicoEconomics and outcomes research, 2020-01, Vol.12, p.481-497

2020

Volltextzugriff (PDF)

Specialty drug coverage varies between health plans' medical and pharmacy benefit policies

Journal of managed care & specialty pharmacy, 2023-06, Vol.29 (6), p.607-613

2023

Volltextzugriff (PDF)

Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States

Advances in therapy, 2022-09, Vol.39 (9), p.3933-3956

2022

Volltextzugriff (PDF)

Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review

Neuropsychiatric disease and treatment, 2021-01, Vol.17, p.515-531

2021

Volltextzugriff (PDF)

Cost Estimation of Cardiovascular Disease Events in the US

PharmacoEconomics, 2011-08, Vol.29 (8), p.693-704

2011

Volltextzugriff (PDF)

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

Journal of cystic fibrosis, 2016-03, Vol.15 (2), p.147-157

2016

Volltextzugriff (PDF)

Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System

Journal of managed care & specialty pharmacy, 2019-07, Vol.25 (7), p.823-835

2019

Volltextzugriff (PDF)

Health equity principles for oncology real world evidence studies

The oncologist (Dayton, Ohio), 2024-10, Vol.29 (10), p.e1260-e1271

2024

Volltextzugriff (PDF)

Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States

Value in health, 2009-07, Vol.12 (5), p.666-673

2009

Volltextzugriff (PDF)

Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome

PharmacoEconomics, 2013-06, Vol.31 (6), p.519-531

2013

Volltextzugriff (PDF)

Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients

Frontiers in psychiatry, 2024-08, Vol.15, p.1377174

2024

Volltextzugriff (PDF)

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

BMC psychiatry, 2022-08, Vol.22 (1), p.1-574, Article 574

2022

Volltextzugriff (PDF)

Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups

BMC psychiatry, 2023-04, Vol.23 (1), p.245-245, Article 245

2023

Volltextzugriff (PDF)

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands

European journal of haematology, 2008-12, Vol.81 (6), p.467-474

2008

Volltextzugriff (PDF)

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder

BMC psychiatry, 2022-02, Vol.22 (1), p.114-114, Article 114

2022

Volltextzugriff (PDF)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia

CNS drugs, 2021-10, Vol.35 (10), p.1123-1135

2021

Volltextzugriff (PDF)

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey

BMC psychiatry, 2020-07, Vol.20 (1), p.354-12, Article 354

2020

Volltextzugriff (PDF)

Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey

Patient preference and adherence, 2020-01, Vol.14, p.2043-2054

2020

Volltextzugriff (PDF)

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

BMC psychiatry, 2021-03, Vol.21 (1), p.164-8, Article 164

2021

Volltextzugriff (PDF)

Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015

Alcohol (Fayetteville, N.Y.), 2020-12, Vol.89, p.19-25

2020

Volltextzugriff (PDF)

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic

Neuropsychiatric disease and treatment, 2023-01, Vol.19, p.623-634

2023

Volltextzugriff (PDF)

Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox–Gastaut syndrome

Epilepsy & behavior, 2013-10, Vol.29 (1), p.184-189

2013

Volltextzugriff (PDF)

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands

Annals of hematology, 2010-09, Vol.89 (9), p.919-926

2010

Volltextzugriff (PDF)

Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic

CNS spectrums, 2022-04, Vol.27 (2), p.230-230

2022

Volltextzugriff (PDF)

Weight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia

CNS spectrums, 2022-04, Vol.27 (2), p.240-240

2022

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(87)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review

Specialty drug coverage varies between health plans' medical and pharmacy benefit policies

Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States

Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review

Cost Estimation of Cardiovascular Disease Events in the US

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System

Health equity principles for oncology real world evidence studies

Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States

Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome

Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial

Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey

Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic

Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox–Gastaut syndrome

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands

Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic

Weight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia

Suchergebnisse filtern